Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Targeting MDR1-P-glycoprotein (MDR1-Pgp) in immunochemotherapy of acute myeloid leukemia (AML).

Cianfriglia M.

Ann Ist Super Sanita. 2013;49(2):190-208. doi: DOI: 10.4415/ANN_13_02_11. Review.

2.
3.

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R.

Clin Cancer Res. 2001 Jun;7(6):1490-6. Erratum in: Clin Cancer Res 2002 Jan;8(1):300.

4.

Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.

Takeshita A.

Int J Hematol. 2013 Jun;97(6):703-16. doi: 10.1007/s12185-013-1365-1. Epub 2013 May 26. Review.

PMID:
23709007
5.

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin.

Linenberger ML, Hong T, Flowers D, Sievers EL, Gooley TA, Bennett JM, Berger MS, Leopold LH, Appelbaum FR, Bernstein ID.

Blood. 2001 Aug 15;98(4):988-94.

6.

[Gemtuzumab ozogamicin for treatment of acute myeloid leukemia].

Brotelle T, Lemal R, Moluçon-Chabrot C, Bay JO, Delaunay J, Guièze R.

Bull Cancer. 2014 Feb;101(2):211-8. doi: 10.1684/bdc.2014.1886. Review. French.

PMID:
24557850
7.

Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.

Ricart AD.

Clin Cancer Res. 2011 Oct 15;17(20):6417-27. doi: 10.1158/1078-0432.CCR-11-0486. Review.

8.

Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.

Jerjian TV, Glode AE, Thompson LA, O'Bryant CL.

Pharmacotherapy. 2016 Jan;36(1):99-116. doi: 10.1002/phar.1687. Review.

PMID:
26799352
9.

[The role of gemtuzumab ozogamicin in the treatment of acute myeloid leukemia patients].

Sakamaki H.

Gan To Kagaku Ryoho. 2008 Sep;35(9):1629-34. Japanese.

PMID:
18799927
10.

Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.

Candoni A, Martinelli G, Toffoletti E, Chiarvesio A, Tiribelli M, Malagola M, Piccaluga PP, Michelutti A, Simeone E, Damiani D, Russo D, Fanin R.

Leuk Res. 2008 Dec;32(12):1800-8. doi: 10.1016/j.leukres.2008.05.011. Epub 2008 Jul 14.

PMID:
18621416
11.

Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.

Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G.

Cancer Chemother Pharmacol. 1997;40 Suppl:S13-9. Review.

PMID:
9272128
12.

Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.

Stasi R.

Expert Opin Biol Ther. 2008 Apr;8(4):527-40. doi: 10.1517/14712598.8.4.527 . Review.

PMID:
18352855
13.

Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin.

Duong HK, Sekeres MA.

Clin Interv Aging. 2009;4:197-205. Epub 2009 May 14. Review.

14.

Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin.

Cowan AJ, Laszlo GS, Estey EH, Walter RB.

Front Biosci (Landmark Ed). 2013 Jun 1;18:1311-34. Review.

15.

What happened to anti-CD33 therapy for acute myeloid leukemia?

Jurcic JG.

Curr Hematol Malig Rep. 2012 Mar;7(1):65-73. doi: 10.1007/s11899-011-0103-0. Review.

PMID:
22109628
16.

Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers.

Matsui H, Takeshita A, Naito K, Shinjo K, Shigeno K, Maekawa M, Yamakawa Y, Tanimoto M, Kobayashi M, Ohnishi K, Ohno R.

Leukemia. 2002 May;16(5):813-9.

17.

Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.

Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, Head DR, Weick J, Grever MR, Appelbaum FR, Willman CL.

Blood. 1999 Aug 1;94(3):1086-99.

18.

CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy.

Walter RB, Gooley TA, van der Velden VH, Loken MR, van Dongen JJ, Flowers DA, Bernstein ID, Appelbaum FR.

Blood. 2007 May 15;109(10):4168-70. Epub 2007 Jan 16.

19.

[Therapeutic advances in neoplastic hematology: target therapy anti-CD33].

Di Rocco A, Finolezzi E, Anaclerico B, Calabrese E, Levi A, Trasarti S, Tafuri A.

Clin Ter. 2005 Jul-Aug;156(4):183-6. Review. Italian.

PMID:
16342520
20.

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.

Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, Stone I, Ryan MC, Sussman D, Lyon RP, Zeng W, Harrington KH, Klussman K, Westendorf L, Meyer D, Bernstein ID, Senter PD, Benjamin DR, Drachman JG, McEarchern JA.

Blood. 2013 Aug 22;122(8):1455-63. doi: 10.1182/blood-2013-03-491506. Epub 2013 Jun 14.

Supplemental Content

Support Center